We are live on ! Find out more
PHIO icon

Phio Pharmaceuticals
PHIO

9 hedge funds and large institutions have $516K invested in Phio Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 9 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

350% more funds holding

Funds holding: 2 → 9 (+7)

350% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 2

271% more capital invested

Capital invested by funds: $139K → $516K (+$377K)

0% more ownership

Funds ownership: 0% → 0% (+0%)

Holders
9
Holders Change
+7
Holders Change %
+350%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
MA
MYDA Advisors
New York
+$161K
2
VF
Virtu Financial
New York
+$92K
3
DS
DRW Securities
Illinois
+$69K
4
FAAS
First Allied Advisory Services
California
+$69K
5
Morgan Stanley
Morgan Stanley
New York
+$69K

Top Sellers

Rank Fund Capital Flow
1
TSS
Two Sigma Securities
New York
-$23K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$18K
3
Citadel Advisors
Citadel Advisors
Florida
-$16K
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$14K
5
RJFSA
Raymond James Financial Services Advisors
Florida
-$11K
Name Holding Trade Value Shares
Change 		Change in
Stake
MA
1
MYDA Advisors
New York
$134K +$161K +7 New
Morgan Stanley
2
Morgan Stanley
New York
$67K +$69K +3 New
VF
3
Virtu Financial
New York
$67K +$92K +4 New
FAAS
4
First Allied Advisory Services
California
$64K +$69K +3 New
DS
5
DRW Securities
Illinois
$61K +$69K +3 New
Vanguard Group
6
Vanguard Group
Pennsylvania
$59K +$69K +3 New
HighTower Advisors
7
HighTower Advisors
Illinois
$32K +$46K +2 New
IP
8
Intellectus Partners
California
$16K +$23K +1 New
UBS Group
9
UBS Group
Switzerland
$12K +$23K +1 New
BlackRock
10
BlackRock
New York
$3K – – –
FC
11
Ferris Capital
Massachusetts
$1K – – –
BDWM
12
Brewin Dolphin Wealth Management
Ireland
$3 – – –
Susquehanna International Group
13
Susquehanna International Group
Pennsylvania
– -$18K -1 Closed
TSS
14
Two Sigma Securities
New York
– -$23K -1 Closed
Citadel Advisors
15
Citadel Advisors
Florida
– -$16K – –
Geode Capital Management
16
Geode Capital Management
Massachusetts
– -$14K – –
Northern Trust
17
Northern Trust
Illinois
– -$7K – –
RJFSA
18
Raymond James Financial Services Advisors
Florida
– -$11K – –

PHIO Hedge Fund Activity: Q1 2018 in Review

9 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q1 2018, worth a combined $516K — up 271% from $139K a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new PHIO positions and 2 closed out — a net gain of 7 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was MYDA Advisors, opening a new position worth an estimated $161K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $23K sold.

  • 9 institutional investors held Phio Pharmaceuticals (PHIO) as of Q1 2018, up from 2 in Q4 2017.
  • Funds reported $516K of Phio Pharmaceuticals stock for Q1 2018, up 271% quarter-over-quarter.
  • 9 funds opened new Phio Pharmaceuticals positions in Q1 2018 and 2 closed out, a net change of +7 holders.
  • The largest Phio Pharmaceuticals buyer in Q1 2018 was MYDA Advisors, an estimated $161K added.
  • The largest Phio Pharmaceuticals seller in Q1 2018 was Two Sigma Securities, an estimated $23K sold.

Based on aggregated 13F filings for Q1 2018.